Shenzhen Senboll Biotechnology Co, Ltd., founded in 2017, is led by a founder with over 20 years of deep expertise in life sciences, who previously served as a discipline leader at renowned research institutions in Europe and the United States. The company is dedicated to the independent R&D of innovative biomarkers for digestive diseases and tumors, establishing a comprehensive innovation system spanning "biomarker discovery—diagnostic reagent development—clinical validation." As a national high-tech enterprise integrating R&D, production, operations, and sales, Senboll Biotechnology is headquartered in the Shenzhen Pingshan National Biomedical Innovation Industrial Park—a national-level strategic hub—and boasts advanced research laboratories and a 1,600-square-meter GMP production facility. Upholding the product philosophy of "precise detection, efficient screening, and accessible healthcare," the company provides effective and reliable novel biomarkers for digestive diseases, enhancing clinical diagnostic efficiency.
Vision & Mission Senboll Biotechnology strives to become a global pioneer in digestive disease diagnostics, empowering clinical decision-making and health management with cutting-edge detection technologies. We are committed to advancing life sciences and safeguarding human health.
Core Business Specializing in early detection and precision diagnosis of digestive diseases, we leverage advanced genetic engineering and bioassay platforms to identify highly clinically valuable biomarkers from vast genomic data. Our flagship product—the world's first and China-exclusive REG1A (Regenerating Islet-Derived Protein 1α) ELISA Kit (Medical Device Registration No.: YUEXIEZHUZHUN20252400165)—was approved through Guangdong Medical Products Administration’s Innovation Fast-Track Program and filed with the National Medical Products Administration (NMPA). As a globally pioneering in vitro diagnostic (IVD) device for gastrointestinal diseases, it opens new avenues for early diagnosis.
R&D Capabilities & Intellectual Property Our elite R&D team, led by scientists returning from Europe and the U.S., includes veterans from top-tier research institutions and Fortune 500 companies, with core members averaging 15 years of industry expertise. With annual R&D investment exceeding 35% of revenue, we hold multiple global patents, including our breakthrough REG1A biomarker, which achieves an industry-leading 67.26% sensitivity for intestinal polyps and adenomas. We actively expand our IP portfolio, having filed for international PCT patents to fortify technological barriers.
Quality System & Certifications Adhering to ISO international quality standards and GMP production protocols, we enforce a rigorous quality control system—from raw material procurement to finished product delivery—ensuring batch-to-batch consistency. Equipped with state-of-the-art production and testing instruments, our facility maintains a >99.5% product pass rate, delivering accurate and reliable diagnostic solutions.
Market Network & Clientele Our products have gained broad market recognition for their unique advantages and superior performance. Domestically, we serve over 30 provinces/municipalities, partnering with top-tier hospitals and research institutes, with collaborative studies published in renowned international journals. Globally, we’ve expanded into Southeast Asia, Europe, and North America, contributing to worldwide healthcare.
Honors & Achievements Recognized as a "National High-Tech Enterprise", "Shenzhen Innovative Enterprise", and "Pingshan Outstanding Sci-Tech Company", our products are listed among "Shenzhen High-Tech Products". We regularly showcase innovations at global life science exhibitions and academic conferences, earning widespread acclaim.